Celltrion Inc. develops, manufactures, and markets antibody-based therapies for cancer and autoimmune disorders, leveraging biotechnology and large-scale animal cell culture platforms. Its operations are organized into two business segments: Biopharmaceuticals and Chemical Medicines. The company’s current portfolio includes six biosimilars—Remsima/Inflectra, Truxima, Herzuma, Remsima SC, Uplyma, and Vegzelma—and it has secured approval for its novel drug Zimfentra (CT-P13 SC; US brand name). Celltrion is also broadening its lineup with five newly approved products: Omriclor, Stekima, Aptozuma, Stovoclo & Ossenveld, and Idenzelt.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Celltrion’s R&D is centered on developing and optimizing recombinant monoclonal antibodies using biotechnology and mammalian cell-culture platforms, with a focus on treatments for cancer and autoimmune diseases. The company allocates about 20% of annual sales to R&D to broaden its biosimilar portfolio and advance novel antibody candidates, while strengthening in-house manufacturing capacity and quality-control systems to improve global competitiveness. Celltrion has successfully commercialized several landmark antibody biosimilars, including Remsima (Remicade biosimilar), Truxima (Rituxan biosimilar), Herzuma (Herceptin biosimilar), Uplima (Humira biosimilar), and Begzelma (Avastin biosimilar). Additional biosimilar programs in development include CT-P43, CT-P39, CT-P42, CT-P41, and CT-P47. The company has also secured U.S. marketing approval for Zimfentra, the first subcutaneous infliximab formulation, and completed global Phase 3 trials for Rekirona, an antibody-based COVID-19 treatment. Beyond antibodies, Celltrion is pursuing strategic collaborations with global biotech partners, expanding into chemically synthesized pharmaceuticals for international markets, and operating a dedicated BSL-2 research facility to support development of therapies for infectious viral diseases. In FY2025, the company spent KRW208,049.2 million on its R&D activities, which as a percentage of revenue stood at 49.9% and grew 7.5% YoY.